Published 17 hours ago • loading... • Updated 14 hours ago

MEDIPOST Announces the Exclusive Commercialization License Agreement with Teikoku Seiyaku for Knee Osteoarthritis Treatment CARTISTEM® in Japan

On Dec. 19, 2025, MEDIPOST K.K. granted Teikoku Seiyaku Co., Ltd. an exclusive license for CARTISTEM sales, distribution, and promotion in Japan, with MEDIPOST supplying the drug substance and retaining manufacturing rights.
To accelerate patient access, Teikoku Seiyaku Co., Ltd. will leverage its orthopedic hospital and clinic network to promote and distribute CARTISTEM, expanding its medical representative division.
Since its 2012 approval, CARTISTEM has treated more than 35,000 patients over 13 years and demonstrates cartilage-regenerating effects with potential as a disease-modifying osteoarthritis drug.
Under the deal, MEDIPOST Co., Ltd. secures US$8 million upfront plus a US$10 million short-term regulatory milestone and undisclosed sales-based long-term milestones from Teikoku Seiyaku Co., Ltd.
MEDIPOST, founded in 2000, brings integrated stem cell, clinical development, and CDMO capabilities, while Teikoku Seiyaku Co., Ltd. has prior osteoarthritis ties and a sales agreement with ReqMed Company, Ltd.

Insights by Ground AI

52 Articles

Bennington Banner

+51 Reposted by 51 other sources

Center

MEDIPOST Announces the Exclusive Commercialization License Agreement with Teikoku Seiyaku for Knee Osteoarthritis Treatment CARTISTEM® in Japan

South Korean biotech company secures US$8 million in upfront payment for the joint commercialization of the stem cell therapy CARTISTEM® targeting the Japanese knee osteoarthritis market.

17 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year